

## Inova Academic Accomplishments 2014

For PDF copies of any publications, please email [steven.nathan@inova.org](mailto:steven.nathan@inova.org)

### JOURNAL ARTICLES (accepted, epubS and pubs)

1. King Jr TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the Design and Execution of Clinical Trials. *Am J Respir Crit Care Med* 2014;189:825-831
2. Cullinane AR, Yeager C, Dorward H, Carmona-Rivera C, Wu HP, Moss J, O'Brien KJ, Nathan SD, Meyer KC, Rosas IO, Helip-Wooley A, Markello TC, Huizing M, Gahl WA, Gochuico BR. BLOC-3 Regulation of Galectin-3: Implications for Hermansky-Pudlak Syndrome Pulmonary Fibrosis. *American Journal of Respiratory Cell and Molecular Biology* 2014;50:605-613
3. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer D, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. The ASCEND Trial: A randomized, double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014;370:2083-2092
4. Outcomes after Hospitalization in Idiopathic Pulmonary Fibrosis: a cohort study. Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. *Chest*. 2014 Sep 4. doi: 10.1378/chest.13-2424. [Epub ahead of print]
5. Keyser RE, Woolstenhulme J, Chin L, Nathan SD, Connors G, Drinkard B, Lamberti J, Chan L. Cardiorespiratory Function Before and After Aerobic Exercise Training in Patients with Interstitial Lung Disease. Accepted to *Journal of Cardiopulmonary Rehabilitation and Prevention*
6. Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan M, Ahmad S, Newton K, Weir N, Shlobin OA, Nathan SD. Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Accepted *Res Med* 2014. Available as epub <http://dx.doi.org/10.1016/j.rmed.2014.08.009>

### REVIEWS

1. Nathan SD, Meyer KC. IPF Clinical Trial design and Endpoints. *Current Opinions in Pulmonary Medicine* 2014, 20:000–000 DOI:10.1097/MCP.0000000000000091
2. Nathan SD, King C. Current and Emerging Therapeutic Targets for Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. *Drug Des Devel Ther*. 2014 Jul 2;8:875-85. doi: 10.2147/DDDT.S64907
3. Nathan SD. The Future of Lung Transplantation. accepted *Chest* "Ahead of the Curve" September 16<sup>th</sup>, 2014

### EDITORIALS

1. Nathan SD. Pulmonary hypertension complicating Pulmonary Fibrosis: bad and ugly, but good to treat? *Thorax* 2014;69:107-108
2. Nathan SD. Hypersensitivity pneumonitis and pulmonary hypertension-how the breeze affects the squeeze. *Eur Respir* 2014;44:287-288
3. Nathan SD, Carbone R. Bosentan in pulmonary hypertension due to fibrotic idiopathic interstitial pneumonia: Hidden value in a neutral trial. *Am J Res Crit Care Med* 2014;190:131-132

### LETTER

1. Nathan SD, Brown AW, Weir N. Response to letter Six minute walk distance-effect of instructions. *Chest* 2014;145:1440-1441

### BOOK CHAPTERS AND BOOKS

1. King CS, Nathan SD. The Role of identification and treatment of comorbidities in IPF and other fibrotic lung diseases. *Current Opinions in Pulmonary Medicine*. Editors Richeldi & Flaherty.
2. King CS, Nathan SD. Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For *Pulmonary Hypertension and Interstitial lung disease*. Edited by Baughman, Carbone and Nathan.

3. King C, May C, Williams J, Shlobin OA. Management of right heart failure in the critically ill (pp 475-498). *Cardiac Emergencies in the ICU. Critical Care Clinics* July 2014. Edited by Desai SS, Puri N with consulting editor Carlson RW.
4. Shlobin OA, Nathan SD. Sarcoidosis associated pulmonary hypertension. *Pulmonary Sarcoidosis: A Guide for the Practicing Clinician. Springer Science+Business Media* 2014. Edited by Marc Judson.

#### **ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS**

1. Lydick S, Weinstein A, Chin LMK, Nathan SD, Chan L, Keyser RE. Fatigue and Physical Activity in Patients with Pulmonary Arterial Hypertension. Accepted to American College of Sports Medicine, May 2014.
2. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fishman RS, Glaspole I, Glassberg MK, King TE, Lancaster L, Lederer D, Leff JS, Pereira CA, Sahn SA, Swigris JJ, Noble PW, Valeyre D. Long-term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Integrated Analysis of Data from 4 Clinical Trials. Presented at ATS May 2014.
3. King TE, Castro-Bernardini S, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer D, Nathan SD, Pereira CA, Sahn SA, Sussman RA, Swigris JJ, Noble PW. ASCEND Study: A Randomized, Double-blind, Placebo Controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF). Presented at ATS May 2014.
4. Noble PW, Bradford WZ, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer D, Leff JA, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, King TE. Analysis of Pooled Data from 3 Phase 3, Multinational, Randomized, Double-blind, Placebo Controlled Trials Evaluating Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF). Presented at ATS May 2014.
5. Lederer D, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lancaster L, Leff JA, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Valeyre D, Noble PW. Effect of Treatment with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Meta-analysis of 5 Randomized, Double-blind, Placebo Controlled Clinical Trials. Presented at ATS May 2014.
6. Shlobin OA, Barney J, Engel PJ, Lower EE, Culver DA, Nathan SD, Cordova F, Baughman RP. A Registry of Sarcoidosis associated Pulmonary Hypertension. Presented at ATS May 2014.
7. Boulos AM, Lu M, Levin AM, Massion PP, Midthun DE, Nana-Sinkam P, Arenberg DA, Mazzone PJ, Nathan SD, Wainz R, Silvestri GA, Willey JC. Safety of Bronchoscopic Brush Biopsy in Subjects Recruited for Lung Cancer and COPD Risk Test Validation. Presented at ATS May 2014.
8. Thompson F, Lower EE, Nathan SD, Barney J, Engel PJ, Culver DA, Cordova F, Baughman RP. Fatigue in sarcoidosis associated pulmonary hypertension. Presented at ATS May 2014.
9. Cordova F, Nathan SD, Barney J, Engel PJ, Lower EE, Culver DA, Baughman RP. Characterization of Pulmonary Hypertension Without Elevated Pulmonary Vascular Resistance in Patients with Sarcoidosis: Registry of Sarcoidosis Associated Pulmonary Hypertension Study (ReSAPH). Presented at ATS May 2014.
10. Hong A, Khandhar S, Brown AW, Bogar L, Ahmad S, Shlobin OA, King C, Burton NA, Nathan SD. Hemothorax after Lung Transplantation. Presented at ATS May 2014.
11. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer D, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. The ASCEND Study: A Randomized, Double-blind, Placebo Controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF). Presented at ATS 2014
12. Esposito DB, Lanes SF, Donneyong M, Holick CN, Lasky J, Lederer DJ, Nathan SD, O'Quinn S, Tran TN. Incidence and prevalence of IPF in an insurance claims database: assessing accuracy using medical records. Presented at to ERS 2014.
13. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer D, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. Effect of Design Modifications on Clinical Trial Outcomes in Idiopathic Pulmonary Fibrosis (IPF): Analysis of Data from the ASCEND and CAPACITY (CAP) Studies. Presented at ERS 2014
14. Cohee BM, Brown AW, Shlobin OA, Kiernan JM, Mani H, Fregoso M, Germano K, Nathan SD, Ahmad S. Adenovirus Infection Presenting as a Solitary Mass Lesion with Lymphocytic Effusion in a Lung Transplant Recipient. Presented at Chest 2014.

15. Noble PW, Albera C, Bradford WZ, Costable U, du Bois RM, Glaspole I, Glassberg MK, Lancaster L, Lederer D, Leff JA, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Valeyre D, King TE. Pirfenidone effect on morbidity and mortality for up to 72 weeks in patients with idiopathic pulmonary fibrosis. Presented at ERS Sep 2014.
16. Lederer DJ, Bradford WZ, Fagan EA, Fishman R, Glaspole I, Glassberg MK, Kardatzke D, King TE, Lancaster L, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Noble PW. Sensitivity analyses of the primary endpoint of FVC change in the ASCEND study. Presented at International Colloquium on Lung and Airway Fibrosis Sep 2014.
17. Nathan SD, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lancaster LL, Lederer DJ, Leff JA, Pereira CA, Sahn SA, Swigris JJ, Noble PW, Valeyre D. Long-term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF): Integrated Analysis of Data From 4 Clinical Trials. Presented at International Colloquium on Lung and Airway Fibrosis Sep 2014.
18. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Glaspole I, Glassberg MK, Lancaster L, D Lederer D, Leff JA, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Valeyre D, King TE. Effect of Pirfenidone on Subpopulations of Patients With Idiopathic Pulmonary Fibrosis (IPF). Presented at International Colloquium on Lung and Airway Fibrosis Sep 2014.
19. Fischer A, Steen VD, Nathan SD, Gillies H, Tislow J, Blair C. Categorical changes in 6MWD in patients with connective tissue disease associated pulmonary arterial hypertension receiving ambrisentan over 3-years: an analysis of the ARIES-E database. Accepted to American College of Rheumatology 2014.

#### **PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS**

1. Pulmonary Hypertension: 2014 update. New York Thoracic Society meeting, NYC, NY Feb 1<sup>st</sup>, 2014 (SN)
2. Scleroderma: PAH with ILD versus ILD and PH? International Society for Heart and Lung Transplantation meeting. San Diego April 10<sup>th</sup>, 2014. (SN)
3. Scleroderma in lung transplant pro con debate: International Society for Heart and Lung Transplantation meeting. San Diego April 10<sup>th</sup>, 2014. (OS)
4. Clinical trial design in non-Group I Pulmonary Hypertension. American Thoracic Society May 20<sup>th</sup> 2014 San Diego. (SN)
5. Pulmonary Hypertension with other Lung Diseases: treatment implications American Thoracic Society May 21<sup>st</sup> 2014 San Diego. (SN)
6. Pulmonary Hypertension in IPF: Target to treat or epiphenomenon? World Association for Sarcoidosis and other Granulomatous Diseases (WASOG) conference Kusadasi, Turkey October 11<sup>th</sup>, 2014. (SN)
7. WHO Group 3 Pulmonary Hypertension: Incidence, pathogenesis and assessment. Pulmonary Hypertension Society of Australia and New Zealand annual meeting October 17<sup>th</sup>, 2014. Noosa, QLD, Australia. (SN)
8. Evidence for Therapy in group 3 Pulmonary Hypertension. Pulmonary Hypertension Society of Australia and New Zealand annual meeting October 17<sup>th</sup>, 2014. Noosa, QLD, Australia. (SN)
9. Interstitial Lung Disease: Treatment Update. Fellow Conference, American College of Chest Physicians. Austin, Texas October 25<sup>th</sup>, 2014 (SN)
10. IPF State of the Art Evaluation and Management: Comorbidities in IPF American College of Chest Physicians. Austin, Texas October 27<sup>th</sup>, 2014 (SN)
11. Pharmacotherapy of IPF: Present and Future Therapies and Clinical Trials. American College of Chest Physicians. Austin, Texas October 27<sup>th</sup>, 2014 (SN)
12. Social Work workshop (2 parts) on research at the Society of Transplant Social Workers. Boston Sept 2014 (Jane Harrison)